ANAB · Anaptysbio, Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $234.60M | $91.28M | $17.16M | $10.29M | $63.17M | $75.00M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $135.97M | $163.84M | $98.50M | $88.80M | $98.50M | $80.03M |
| SG&A | $50.74M | $42.39M | $41.95M | $36.64M | $21.49M | $18.85M |
| Total Operating Expenses | $186.71M | $206.23M | $181.57M | $125.44M | $119.99M | $98.88M |
| D&A | $559.0K | $606.0K | $652.0K | $675.0K | $619.0K | $559.0K |
| Operating Income | $47.90M | ($114.95M) | ($164.41M) | ($115.15M) | ($56.81M) | ($23.88M) |
| Interest Expense | - | - | - | - | $0 | $0 |
| Income Tax | $164.0K | $3.0K | ($4.0K) | $24.0K | $0 | $0 |
| Net Income | ($13.23M) | ($145.23M) | ($163.62M) | ($128.72M) | ($57.80M) | ($19.93M) |
| EPS - Basic | ($0.31) | ($3.41) | ($4.05) | ($3.05) | ($0.49) | - |
| EPS - Diluted | ($0.31) | ($3.41) | ($4.05) | ($3.05) | ($0.49) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $238.20M | $123.08M | $35.97M | $71.31M | $495.73M | $250.46M |
| Accounts Receivable | $33.85M | $40.77M | $6.85M | $1.42M | $876.0K | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $3.87M | $4.00M | $4.70M | $2.78M | $1.74M | $4.22M |
| Current Assets | $350.25M | $431.88M | $406.83M | $447.20M | $553.88M | $396.56M |
| Total Assets | $364.39M | $483.83M | $452.39M | $610.38M | $643.07M | $416.55M |
| Current Liabilities | $38.63M | $45.43M | $37.44M | $26.05M | $16.10M | $19.82M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | - | - | - | - | - | - |
| Stockholders' Equity | $37.21M | $70.87M | $88.10M | $262.10M | $356.43M | $396.73M |
| Retained Earnings | ($772.56M) | ($759.33M) | ($614.10M) | ($450.48M) | ($321.75M) | ($263.96M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $19.70M | ($135.34M) | ($120.80M) | ($73.59M) | ($45.92M) | ($14.16M) |
| Investing Cash Flow | $228.03M | $95.40M | $144.75M | ($394.85M) | $38.84M | $94.47M |
| Financing Cash Flow | ($132.61M) | $127.05M | ($59.30M) | $44.02M | $252.30M | ($879.0K) |
| CapEx | $87.0K | $358.0K | $807.0K | $358.0K | $1.37M | $569.0K |
| Free Cash Flow | $19.61M | ($135.69M) | ($121.61M) | ($73.95M) | ($47.29M) | ($14.73M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | 20.4% | -125.9% | -958.3% | -1119.4% | -89.9% | -31.8% |
| EBITDA margin | 20.7% | -125.3% | -954.5% | -1112.9% | -89.0% | -31.1% |
| Net margin | -5.6% | -159.1% | -953.7% | -1251.3% | -91.5% | -26.6% |
| Free cash flow margin | 8.4% | -148.7% | -708.8% | -718.9% | -74.8% | -19.6% |
| FCF / Net income | -1.48 | 0.93 | 0.74 | 0.57 | 0.82 | 0.74 |
| R&D / Revenue | 58.0% | 179.5% | 574.1% | 863.2% | 155.9% | 106.7% |
| SG&A / Revenue | 21.6% | 46.4% | 244.5% | 356.2% | 34.0% | 25.1% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -3.6% | -30.0% | -36.2% | -21.1% | -9.0% | -4.8% |
| Return on equity | -35.6% | -204.9% | -185.7% | -49.1% | -16.2% | -5.0% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 |
| Quick ratio | 9.07 | 9.51 | 10.87 | 17.16 | 34.40 | 20.01 |
| Cash ratio | 6.17 | 2.71 | 0.96 | 2.74 | 30.79 | 12.64 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 9.79 | 6.83 | 5.13 | 2.33 | 1.80 | 1.05 |
| Liabilities / Assets | - | - | - | - | - | - |
| Efficiency | ||||||
| Asset turnover | 0.64 | 0.19 | 0.04 | 0.02 | 0.10 | 0.18 |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | 53d | 163d | 146d | 50d | 5d | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 25.0x | 3.5x | 4.4x | 2.2x | 1.8x | - |
| P / S | 4.0x | 2.7x | 22.4x | 56.6x | 10.0x | - |
| EV / EBITDA | 14.3x | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 157.0% | 432.0% | 66.8% | -83.7% | -15.8% | 837.5% |
| Revenue CAGR (3y) | 183.6% | 13.1% | -38.8% | 8.7% | - | 65.0% |
| Revenue CAGR (5y) | 25.6% | 62.7% | - | -9.2% | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | - | 30.1% | -42.8% | -102.7% | -137.9% | 77.8% |
| Net income growth (YoY) | 90.9% | 11.2% | -27.1% | -122.7% | -190.0% | 79.5% |
| EPS growth (YoY) | 91.0% | 15.8% | -33.0% | -526.0% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | - | -11.6% | -64.4% | -56.4% | -221.1% | 79.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -47.5% | -19.6% | -66.4% | -26.5% | -10.2% | -2.0% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$234.60M totalRoyalty Management Company$234.60M · 100.0%
Product / service
$134.70M totalAnaptys Bio Generated Anti PD1 Jemperli Dostarlimab$125.00M · 92.8%
License$9.50M · 7.1%
Transaction Service$200.0K · 0.1%
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
4/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing ANAPTYSBIO against the 5 most active filers in the same SIC group.